Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Enforcement Of NDI Filings Lacks Consistency, Industry Reps Say

This article was originally published in The Tan Sheet

Executive Summary

Appropriate FDA enforcement of 75-day premarket notifications for new dietary ingredients should be consistent for all manufacturers, according to Pharmavite VP-Regulatory & Legal Affairs Paul Bolar
Advertisement

Related Content

Supplement GMPs, NDI Guidance Should Top CFSAN 2007 Priority List – CRN
Supplement GMPs, NDI Guidance Should Top CFSAN 2007 Priority List – CRN
Supplement GMPs, NDI Guidance Should Top CFSAN 2007 Priority List – CRN
Andro Targeted By FDA In Coordination With Capitol Hill Action
Andro Targeted By FDA In Coordination With Capitol Hill Action

Topics

Advertisement
UsernamePublicRestriction

Register

PS097538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel